302 related articles for article (PubMed ID: 34484217)
1.
Yaegashi LB; Baldavira CM; Prieto TG; Machado-Rugolo J; Velosa APP; da Silveira LKR; Assato A; Ab'Saber AM; Falzoni R; Takagaki T; Silva PL; Teodoro WR; Capelozzi VL
Front Immunol; 2021; 12():714230. PubMed ID: 34484217
[TBL] [Abstract][Full Text] [Related]
2. Low PD-1 Expression in Cytotoxic CD8
Mazzaschi G; Madeddu D; Falco A; Bocchialini G; Goldoni M; Sogni F; Armani G; Lagrasta CA; Lorusso B; Mangiaracina C; Vilella R; Frati C; Alfieri R; Ampollini L; Veneziani M; Silini EM; Ardizzoni A; Urbanek K; Aversa F; Quaini F; Tiseo M
Clin Cancer Res; 2018 Jan; 24(2):407-419. PubMed ID: 29074606
[No Abstract] [Full Text] [Related]
3. High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer.
Massarelli E; Lam VK; Parra ER; Rodriguez-Canales J; Behrens C; Diao L; Wang J; Blando J; Byers LA; Yanamandra N; Brett S; Morley P; Sharma P; Allison J; Wistuba II; Heymach JV
J Immunother Cancer; 2019 Dec; 7(1):351. PubMed ID: 31843013
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of PD-L1-positive cancer-associated fibroblasts in pN0M0 non-small cell lung cancer.
Teramoto K; Igarashi T; Kataoka Y; Ishida M; Hanaoka J; Sumimoto H; Daigo Y
Lung Cancer; 2019 Nov; 137():56-63. PubMed ID: 31546072
[TBL] [Abstract][Full Text] [Related]
5. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
6. Dynamic changes in PD-L1 expression and CD8
Choe EA; Cha YJ; Kim JH; Pyo KH; Hong MH; Park SY; Shim HS; Jung I; Lee CY; Cho BC; Kim HR
Lung Cancer; 2019 Oct; 136():30-36. PubMed ID: 31421259
[TBL] [Abstract][Full Text] [Related]
7. Variants in Epithelial-Mesenchymal Transition and Immune Checkpoint Genes Are Associated With Immune Cell Profiles and Predict Survival in Non-Small Cell Lung Cancer.
Parra ER; Jiang M; Machado-Rugolo J; Yaegashi LB; Prieto T; Farhat C; de Sá VK; Nagai MA; de Lima VCC; Takagaki T; Terra R; Fabro AT; Capelozzi VL
Arch Pathol Lab Med; 2020 Oct; 144(10):1234-1244. PubMed ID: 32150457
[TBL] [Abstract][Full Text] [Related]
8. Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer.
Yim J; Koh J; Kim S; Song SG; Ahn HK; Kim YA; Jeon YK; Chung DH
Eur J Cancer; 2020 Jul; 133():74-85. PubMed ID: 32447027
[TBL] [Abstract][Full Text] [Related]
9. Peritumoral CD90+CD73+ cells possess immunosuppressive features in human non-small cell lung cancer.
Wang L; Yang H; Dorn P; Berezowska S; Blank F; Wotzkow C; Marti TM; Peng RW; Harrer N; Sommergruber W; Kocher GJ; Schmid RA; Hall SRR
EBioMedicine; 2021 Nov; 73():103664. PubMed ID: 34740105
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated immune factors are associated with recurrence and metastasis in non-small cell lung cancer.
Yan X; Jiao SC; Zhang GQ; Guan Y; Wang JL
Cancer Gene Ther; 2017 Feb; 24(2):57-63. PubMed ID: 28084319
[TBL] [Abstract][Full Text] [Related]
11. The intratumoral distribution influences the prognostic impact of CD68- and CD204-positive macrophages in non-small cell lung cancer.
Li Z; Maeda D; Yoshida M; Umakoshi M; Nanjo H; Shiraishi K; Saito M; Kohno T; Konno H; Saito H; Minamiya Y; Goto A
Lung Cancer; 2018 Sep; 123():127-135. PubMed ID: 30089583
[TBL] [Abstract][Full Text] [Related]
12. Effect of neoadjuvant chemotherapy on the immune microenvironment in non-small cell lung carcinomas as determined by multiplex immunofluorescence and image analysis approaches.
Parra ER; Villalobos P; Behrens C; Jiang M; Pataer A; Swisher SG; William WN; Zhang J; Lee J; Cascone T; Heymach JV; Forget MA; Haymaker C; Bernatchez C; Kalhor N; Weissferdt A; Moran C; Zhang J; Vaporciyan A; Gibbons DL; Sepesi B; Wistuba II
J Immunother Cancer; 2018 Jun; 6(1):48. PubMed ID: 29871672
[TBL] [Abstract][Full Text] [Related]
13. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
14. Impact of PD-L1 and PD-1 Expression on the Prognostic Significance of CD8
Munari E; Marconi M; Querzoli G; Lunardi G; Bertoglio P; Ciompi F; Tosadori A; Eccher A; Tumino N; Quatrini L; Vacca P; Rossi G; Cavazza A; Martignoni G; Brunelli M; Netto GJ; Moretta L; Zamboni G; Bogina G
Front Immunol; 2021; 12():680973. PubMed ID: 34122444
[TBL] [Abstract][Full Text] [Related]
15. Cancer-Associated Fibroblasts Accelerate Malignant Progression of Non-Small Cell Lung Cancer via Connexin 43-Formed Unidirectional Gap Junctional Intercellular Communication.
Luo M; Luo Y; Mao N; Huang G; Teng C; Wang H; Wu J; Liao X; Yang J
Cell Physiol Biochem; 2018; 51(1):315-336. PubMed ID: 30453281
[TBL] [Abstract][Full Text] [Related]
16. Spatial interaction and functional status of CD68
Liu X; Zhang Z; Yuan J; Yu J; Chen D
Front Immunol; 2024; 15():1396719. PubMed ID: 38799432
[TBL] [Abstract][Full Text] [Related]
17. The implications of clinical risk factors, CAR index, and compositional changes of immune cells on hyperprogressive disease in non-small cell lung cancer patients receiving immunotherapy.
Kim SR; Chun SH; Kim JR; Kim SY; Seo JY; Jung CK; Gil BM; Kim JO; Ko YH; Woo IS; Shim BY; Hong SH; Kang JH
BMC Cancer; 2021 Jan; 21(1):19. PubMed ID: 33402127
[TBL] [Abstract][Full Text] [Related]
18. Prognostic impact of CD34 and SMA in cancer-associated fibroblasts in stage I-III NSCLC.
Schulze AB; Schmidt LH; Heitkötter B; Huss S; Mohr M; Marra A; Hillejan L; Görlich D; Barth PJ; Rehkämper J; Evers G
Thorac Cancer; 2020 Jan; 11(1):120-129. PubMed ID: 31760702
[TBL] [Abstract][Full Text] [Related]
19. Tissue analyses reveal a potential immune-adjuvant function of FAP-1 positive fibroblasts in non-small cell lung cancer.
Kilvaer TK; Rakaee M; Hellevik T; Østman A; Strell C; Bremnes RM; Busund LT; Dønnem T; Martinez-Zubiaurre I
PLoS One; 2018; 13(2):e0192157. PubMed ID: 29415055
[TBL] [Abstract][Full Text] [Related]
20. [CD45RO⁺ Memory T Lymphocytes As A Candidate Marker for Non-small Cell Lung Cancer].
Tan Q; Li H; Yu M; Tang X; Tan J; Zhang S; Wang J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):254-264. PubMed ID: 33910273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
